Q-omics provides the consensus-scored CCDC3 profile across patient tissues and cancer cell-line models. CCDC3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC3 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC3 RNA expression shows 14,805 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KICH, and TGCT as cancer lineages where CCDC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC3 survival associations across molecular data types. CCDC3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC3 RNA expression–survival associations across cancer types. High CCDC3 expression shows unfavorable associations in ACC, KIRP, OV and BLCA, but favorable associations in LUAD and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC3 RNA expression.
This table summarizes CCDC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC3 shows lower tumor expression in KICH, THCA, BLCA, KIRP and UCEC and higher tumor expression in COAD. The KICH box plot shows higher CCDC3 RNA expression in normal versus tumor tissue (log2 FC = −2.813, t-test p < 0.001).
This table shows molecular features associated with CCDC3 in patient tissues and cancer cell lines. In patient samples, CCDC3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
